These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37226576)

  • 1. Considerations on the use of different comparators in pharmacovigilance: A methodological review.
    Gravel CA; Douros A
    Br J Clin Pharmacol; 2023 Sep; 89(9):2671-2676. PubMed ID: 37226576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparators in Pharmacovigilance: A Quasi-Quantification Bias Analysis.
    Gravel CA; Bai W; Douros A
    Drug Saf; 2024 Aug; 47(8):809-819. PubMed ID: 38703312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A meta-epidemiological study found lack of transparency and poor reporting of disproportionality analyses for signal detection in pharmacovigilance databases.
    Khouri C; Revol B; Lepelley M; Mouffak A; Bernardeau C; Salvo F; Pariente A; Roustit M; Cracowski JL
    J Clin Epidemiol; 2021 Nov; 139():191-198. PubMed ID: 34329725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.
    Caster O; Aoki Y; Gattepaille LM; Grundmark B
    Drug Saf; 2020 May; 43(5):479-487. PubMed ID: 32008183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploration of statistical shrinkage parameters of disproportionality methods in spontaneous reporting system of China.
    Wang J; Ye XF; Guo XJ; Zhu TT; Qi N; Hou YF; Zhang TY; Shi WT; Wei X; Liu YZ; Wu GZ; He J
    Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):962-70. PubMed ID: 26095121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: An example using sodium/glucose cotransporter 2 inhibitors.
    Alkabbani W; Gamble JM
    Br J Clin Pharmacol; 2023 Feb; 89(2):431-439. PubMed ID: 34964156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Role of Disproportionality Analysis of Pharmacovigilance Databases in Safety Regulatory Actions: a Systematic Review.
    Dias P; Penedones A; Alves C; Ribeiro CF; Marques FB
    Curr Drug Saf; 2015; 10(3):234-50. PubMed ID: 26219291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of statistical signal detection methods within and across spontaneous reporting databases.
    Candore G; Juhlin K; Manlik K; Thakrar B; Quarcoo N; Seabroke S; Wisniewski A; Slattery J
    Drug Saf; 2015 Jun; 38(6):577-87. PubMed ID: 25899605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.
    Sandberg L; Taavola H; Aoki Y; Chandler R; Norén GN
    Drug Saf; 2020 Oct; 43(10):999-1009. PubMed ID: 32564242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement.
    Fusaroli M; Salvo F; Begaud B; AlShammari TM; Bate A; Battini V; Brueckner A; Candore G; Carnovale C; Crisafulli S; Cutroneo PM; Dolladille C; Drici MD; Faillie JL; Goldman A; Hauben M; Herdeiro MT; Mahaux O; Manlik K; Montastruc F; Noguchi Y; Norén GN; Noseda R; Onakpoya IJ; Pariente A; Poluzzi E; Salem M; Sartori D; Trinh NTH; Tuccori M; van Hunsel F; van Puijenbroek E; Raschi E; Khouri C
    Drug Saf; 2024 Jun; 47(6):575-584. PubMed ID: 38713346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
    Trippe ZA; Brendani B; Meier C; Lewis D
    Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous reporting of adverse drug reactions as an outlet for patient dismay? The case of Levothyrox® change of excipients.
    Romani S; Fresse A; Parassol-Girard N; Gerard A; Levraut M; Yamani S; Van Obberghen EK; Pariente A; Rocher F; Viard D; Drici MD
    Fundam Clin Pharmacol; 2022 Jun; 36(3):553-562. PubMed ID: 34989440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.
    Berbain T; Pariente A; Miremont-Salamé G; Grandvuillemin A; Micallef J; Chouchana L; Benkebil M; Théophile H;
    Drug Saf; 2020 Mar; 43(3):243-253. PubMed ID: 31974775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
    Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
    Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.
    Fusaroli M; Salvo F; Begaud B; AlShammari TM; Bate A; Battini V; Brueckner A; Candore G; Carnovale C; Crisafulli S; Cutroneo PM; Dolladille C; Drici MD; Faillie JL; Goldman A; Hauben M; Herdeiro MT; Mahaux O; Manlik K; Montastruc F; Noguchi Y; Norén GN; Noseda R; Onakpoya IJ; Pariente A; Poluzzi E; Salem M; Sartori D; Trinh NTH; Tuccori M; van Hunsel F; van Puijenbroek E; Raschi E; Khouri C
    Drug Saf; 2024 Jun; 47(6):585-599. PubMed ID: 38713347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
    Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
    Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The value of time-to-onset in statistical signal detection of adverse drug reactions: a comparison with disproportionality analysis in spontaneous reports from the Netherlands.
    Scholl JH; van Puijenbroek EP
    Pharmacoepidemiol Drug Saf; 2016 Dec; 25(12):1361-1367. PubMed ID: 27686554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases.
    Khouri C; Petit C; Tod M; Lepelley M; Revol B; Roustit M; Cracowski JL
    J Clin Epidemiol; 2021 Jun; 134():14-21. PubMed ID: 33508405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New exploration of signal detection of Regional Risks from the perspective of data mining: a pharmacovigilance analysis based on spontaneous reporting data in Zhenjiang, China.
    Liu Y; Xu X; Yang J; Zhang Y; He M; Liao W; Wang N; Liu P
    Expert Opin Drug Saf; 2024 Jul; 23(7):893-904. PubMed ID: 38009292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.